title: Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy.
abstract: OBJECTIVE
  The goal of this study was to investigate the local tumor blood supply parameters relative tumor blood volume (rTBV) and transfer coefficient (K(trans)) measurable with dynamic contrast enhanced computed tomography (DCE-CT) in patients with non-small-cell lung cancer (NSCLC) scheduled for radiation therapy (RT).
  
  
  METHODS
  rTBV and K(trans) were measured before RT in 31 patients with clinically inoperable NSCLC (Stages I-III), which received (n=19) or did not receive (n=12) induction chemotherapy (IChT). Possible links between rTBV and K(trans) and time-to-progression (TTP), overall survival (OS) and maximum standardized uptake value (SUV(max)) from fluorodeoxyglucose positron emission tomography as well as histology were analyzed.
  
  
  RESULTS
  NSCLC showed a wide range of rTBV and K(trans) values as estimated by DCE-CT (6.4±0.6ml/100ml and 18.2±1.5ml/100ml/min correspondingly). A significant difference in rTBV values in patients with IChT (4.6±0.6ml/100ml) and without IChT (7.5±0.9ml/100ml; p=0.023), depending on the number of cycles of the IChT and the clinical stage was found. A negative correlation between rTBV and TTP was revealed only in RT patients up-staged by FDG-PET/CT from stage III to stage IV (n=7, r=-0.96, p=0.0006). An inverse correlation between K(trans) and TTP (n=24, r=-0.53, p=0.008) was observed in all RT patients. No relevant correlation was detected between rTBV, K(trans) and SUV(max) or histologic subtypes and grading.
  
  
  CONCLUSIONS
  Tumor blood supply parameters derived from DCE-CT are useful to characterize tumor vascularization before radiotherapy in patients with NSCLC and data on outcome prediction are supplemented.
authors.affiliation: OncoRay - Center for Radiation Research in Oncology, Biological and Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Germany.
authors.forename: Kornelia Szluha
authors.initials: KS
authors.lastname: Lazanyi
authors.forename: Andrij
authors.initials: A
authors.lastname: Abramyuk
authors.forename: Gunter
authors.initials: G
authors.lastname: Wolf
authors.forename: Sergey
authors.initials: S
authors.lastname: Tokalov
authors.forename: Klaus
authors.initials: K
authors.lastname: Zöphel
authors.forename: Steffen
authors.initials: S
authors.lastname: Appold
authors.forename: Thomas
authors.initials: T
authors.lastname: Herrmann
authors.forename: Michael
authors.initials: M
authors.lastname: Baumann
authors.forename: Nasreddin
authors.initials: N
authors.lastname: Abolmaali
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D004358:Drug Therapy; D005240:Feasibility Studies; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011856:Radiographic Image Enhancement; D011881:Radiotherapy, Computer-Assisted; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18